The metabolic syndrome affl icts approximately 25% of the US adult population ( 1 ) with a similar prevalence in other populations in rough proportion to their degree of 'Westernization'. Subjects with metabolic syndrome are at increased risk for stroke ( 2 ), coronary heart disease (CHD)-death, and death from any cause ( 3, 4 ) . Metabolic syndrome is defi ned by central obesity, elevated triglyceride (TG) levels, decreased HDL cholesterol (HDL-C) levels, and mild elevations of glucose and blood pressure; numerous physiologic dysfunctions contribute to the overall pathology. For instance, elevated blood pressure is thought to be the result of dysfunctional endothelium-dependent vasodilation and progressive arterial stiffening ( 5 ). Also associated with the metabolic syndrome is a preponderance of small, dense LDL particles ( 6 ) and an increased thrombotic tendency ( 7 ) . Although lifestyle changes (diet and exercise) can improve many of these conditions, pharmacotherapy is often needed to normalize individual components.
the ERN placebos contained 50 mg rapid-release niacin, which is enough to cause a mild fl ushing response. The study coordinator assigned each treatment a letter (A-D) and the biostatistician (J.V.P.) generated the randomization schedule using an algorithm as described above. The randomization schedule was then given to the staff at Sanford Clinic who enrolled each participant and blindly assigned them to their treatment group. Subjects were asked at 0, 8, and 16 weeks to report the previous week's fl ushing frequency and intensity.
Lipid and vascular data collection took place at weeks 0 and 16. Subjects were asked to fast for at least 8 h prior to each visit. Upon arriving at the dedicated study room, the digital tonometry test (below) was administered fi rst ( ‫ف‬ 40 minutes) followed by a blood draw for fasting lipids. Blood samples were drawn, plasma was separated within 30 min, and samples were stored at Ϫ 70°C. Compliance to treatment was assessed by pill count for both treatments and also (for P-OM3 treatment) by changes in the omega-3 index (OMX), which is the red blood cell (RBC) FA weight percent of EPA and DHA. All subjects were >80% compliant by pill count. The effi cacy of blinding was assessed by a questionnaire after the study ended.
Plasma lipids
Plasma lipids and lipoproteins for study eligibility were measured using standard hospital laboratory techniques, but for endpoint analysis (weeks 0 and 16), these were assessed by ultracentrifugation-based Vertical Auto Profi le (VAP; Atherotech, Birmingham, AL). The correlation between the hospital and VAP methods for TG was 0.95 with a Deming regression slope (95% CI) = 1.02 (0.93, 1.12).
Digital tonometry
Reactive hyperemia index (RHI) was measured using an Endo-PAT2000 (Itamar Medical Ltd., Caesarea, Israel). The Endo-PAT uses pneumatic probes placed on the subject's fi ngertips to estimate pulsatile arterial volume and thus, changes in blood fl ow. Probes were placed on symmetrical fi ngertips, generally the index fi nger of each hand, a blood pressure cuff was loosely placed on the subject's dominant arm, and a baseline reading was obtained. After 3 min, the cuff was infl ated to >300 mmHg to occlude blood fl ow for 5 min and then released. The RHI was obtained by comparing the increase in digital pulse volume in the occluded arm to that in the control arm per the method of Bonetti et al. ( 21 ) . The Framingham RHI (fRHI), a different approach to analyzing the data than suggested by the manufacturer, was also determined ( 22 ) . The Endo-PAT2000 also estimates the augmentation index (AI), which is a measure of arterial stiffness. It is defi ned as the proportion of central pulse pressure due to the late systolic peak, which is in turn attributed to the refl ected pulse wave ( 23 ) . All Endo-PAT measures were made by the same technician trained and certifi ed by Itamar whose specialists reviewed all Endo-PAT tracings to confi rm the quality of the data.
RBC FAs
RBC FA composition was measured to document compliance with P-OM3 and was analyzed by the HS-Omega-3 Index® methodology as previously described ( 24 ) . Fatty acid methyl esters were generated from erythrocytes by acid trans -esterifi cation and analyzed by gas chromatography using a GC2010 Gas Chromatograph (Shimadzu, Columbia, MD) equipped with a SP2560, 100-m column (Supelco, Bellefonte, PA) using hydrogen as carrier gas. FAs were identifi ed by comparison with a standard mixture of FAs characteristic of erythrocytes and expressed as a percentage of total identifi ed FAs after response factor correction.
Statistical methods
The changes in responses were modeled as the dependent variables, with adjustment for baseline values due to chance early for ineffi cacy ( 12 )] Prescription omega-3 acid ethyl esters (P-OM3) are also effective in reducing serum TG ( 13, 14 ) and have been shown to reduce risk and improve survival in the setting of CHD (15) (16) (17) . Both agents have also been reported to improve vascular function ( 18, 19 ) . Here, we sought to measure the effects of these two agents, separately and in combination, on lipid risk parameters and markers of vascular disease (e.g., endothelial dysfunction and arterial stiffness) in metabolic syndrome patients.
METHODS

Participants and study location
The study was conducted at Sanford Research/USD in cooperation with Sanford Clinic-Clinical Research Services in Sioux Falls, South Dakota. Subjects with metabolic syndrome were recruited by advertisements and from booths at local health fairs. Those expressing interest in participation were screened by a phone interview, and qualifi ers were asked to attend a screening visit where informed consent was obtained. Blood pressure, morphometry, and a lipid panel were collected. Inclusion criteria were: age 40 to 69 years; BMI 25 to 40 kg/m 2 ; fasting TG, 150 to 750 mg/dl; HDL-C > 10 mg/dl; and the ratio of TG/HDL-C > 3.5. Exclusion criteria included: presence of other secondary causes of dyslipidemia or hyperglycemia such as hepatic, renal, thyroid, or other endocrine diseases; history of hypersensitivity to niacin or fi sh oils; history of gout, hepatitis, peptic ulcer, or cardiovascular disease; presence of diabetes mellitus; use of any dietary supplements providing more than 50 mg of niacin or 100 mg of fi sh oil omega-3 fatty acids (n-3 FAs); use of any herbal preparations or weight-loss products; use of any lipid-lowering drugs (other than statins) for at least four weeks prior to screening for the study; medically-required treatment with nitrates, calcium channel blockers, or adrenergic blocking agents; hemoglobin < 12 g/dl; LDL-C > 145 mg/dl; or known substance abuse. The protocol was approved by the Institutional Review Board at the University of South Dakota and informed consent was required prior to participation. The study was registered at clinicaltrials.gov (NCT00286234).
Study design
This was a randomized, double-blind, placebo-controlled clinical trial with a 2 × 2 factorial treatment design ( Fig. 1 ). Group size was determined from a pilot study ( 20 ) and was originally powered to an alternative outcome (the rate of appearance of nonesterifi ed FAs in the plasma). The power estimates from the pilot study for the lipid endpoints measured here are given in supplementary Table I ; vascular data were not collected in the pilot study. Power to detect the main effects of each agent on the primary lipid endpoints was >80% except for that of P-OM3 on HDL-C and nonHDL-C. After initially qualifying for the study, subjects began a 6-week, diet-stabilization, dual-placebo, run-in phase (singleblind) in which noncompliant subjects (i.e., <80% compliant) would have potentially been identifi ed and excluded (but none were). Those subjects completing the run-in phase were randomly assigned using permuted blocks of four (with stratifi cation for gender) to 16 weeks of treatment to either dual placebo, extended-release niacin (ERN, Niaspan, Abbott Labs, 2g/d), P-OM3 (Lovaza, GlaxoSmithKline Pharmaceuticals, 4g/d), or the combination. To improve tolerance, ERN was titrated up over the fi rst month by adding 500 mg to the daily dose each week, to achieve the fi nal 2 g/d ( Fig. 1 ). All subjects (placebo and active) were additionally asked to take aspirin (81 mg) prior to dinner to reduce fl ushing. In order to improve blinding to ERN,
Baseline characteristics
Subjects were recruited into the study between August 2007 and October 2008. Seventy-one patients entered the single-blind placebo run-in phase. Three subjects did not return for the baseline visit and seven were lost to follow-up. One subject was included in the study but excluded from analysis when it was recognized that his BMI was greater than the inclusion criterion. One subject had to be excluded from the vascular endpoints due to prior surgery on one index fi nger that was not appreciated at screening, which prevented him from being tested by EndoPat, and EndoPat data from another was removed as an extreme outlier with problematic baseline measurement. Thus, the fi nal sample included 58 subjects for vascular endpoints and 60 for lipid endpoints. Overall, the subjects demonstrated the characteristics of the metabolic syndrome including high TG, low HDL-C, elevated BMI including waist circumferences of 97 (92, 105) for females and 107 (98, 112) for males, mild hypertension, and mild hyperglycemia, indicating their condition was stable and did not change during the run-in phase ( Tables 1 and 2 ). Except for nonHDL-C, subjects were similar at baseline for primary endpoints ( Table 2 ). The differences related to the small sample size per group. Because the power to detect interactions was low (<30%), the groups were tested using a one-way ANCOVA with Dunnett adjustment for multiple comparisons to the placebo group. Residuals were examined for normality and homogeneity, and a natural log transformation was used as needed for improved model assumptions. The fl ushing response was examined using McNemar's exact test from baseline to 8 and 16 weeks for each treatment group. P -values < 0.05 were considered statistically signifi cant. Analyses were performed using SAS® software (version 9.2; SAS Institute Inc., Cary, NC) and JMP® software (version 8.0.2.2; SAS Institute Inc., Cary, NC).
RESULTS
Participant fl ow and blinding
A diagram representing the fl ow of subjects through the study is given in Fig. 1 . At the completion of the study, the majority (38; 63%) of subjects guessed they were taking ERN and 22 (37%) guessed they were on active P-OM3 treatment, but there was no difference between the guesses of subjects in the placebo or treatment groups (Fisher P = 0.43). Thus, the subjects were effectively blinded to treatment. VLDL-C by 19% (5.3 mg/dl). The effect of P-OM3 was to reduce serum TG by 13% (26 mg/dl) and VLDL-C by 12% (3.5 mg/dl). Combination treatment increased HDL-C by 7.8 mg/dl, and decreased TG by 33% (72 mg/dl) and VLDL-C by 27% (8.9 mg/dl). The TG reduction with combination treatment was greater than P-OM3 alone but was not greater than ERN ( P = 0.09). Combination treatment had the greatest impact on lipoprotein subfractions, where improvements in particle density were observed. Subjects on combination therapy and on ERN had increased levels of small, dense HDL 3 ; however, only subjects on combination therapy received the benefi t of increased larger, buoyant HDL 2 . VLDL 1+2 -C decreased more with combination treatment that with either monotherapy . Similar improvements were observed for LDL, which were shifted toward a greater proportion of large, buoyant particles refl ected by an increased LDL 1 + inclusion criteria used here were shown by McLaughlin et al. ( 25, 26 ) to be highly predictive of insulin resistance. The OMX increased signifi cantly in the P-OM3 groups indicating good compliance with treatment (supplementary Fig. I ). Table 2 reports the baseline levels for lipid and vascular endpoints along with details of the lipoprotein profi le from the VAP analysis. Table 3 reports the treatment effects adjusted for baseline. In order to satisfy test assumptions, TG and other indicated secondary endpoints were log-transformed, meaning that the effects of treatment are best interpreted as proportional instead of absolute changes; however, for simplicity, the absolute changes from baseline are also indicated. ERN increased HDL-C by 5.4 mg/dl, and reduced TG by 21% (39 mg/dl) and 
Effects on lipid and lipoprotein levels
DISCUSSION
We compared the single and combined effects of ERN and P-OM3 on the dyslipidemia and vascular dysfunction characteristic of the metabolic syndrome. We found that ERN broadly improved dyslipidemia and vascular stiffness whereas P-OM3 improved hypertriglyceridemia. The combination had additive effects on TG beyond that of P-OM3 alone but not beyond ERN alone. Combination therapy LDL 2 in subjects on combination therapy, and time to peak LDL in the combination group. Table 3 also shows the adjusted treatment effects on vascular function. ERN signifi cantly reduced the AI, a marker of vascular stiffness, by 3.5 units. No effect on this measure was observed in either P-OM3 or combination treatments. No signifi cant effect of either agent (singly or combined) was observed on endothelial function measured by RHI or on blood pressure (data not shown). The effects of treatment on fl ushing are shown in supplementary Table II . The expected fl ushing effect of niacin was noted with combination therapy at the 8 and 16 week visits; P-OM3 did not prevent it.
Effects on vascular function
Effects on endpoints as a function of changes in RBC n-3 FAs
Robust biomarkers of tissue incorporation exist for P-OM3 therapy (i.e., OMX). Use of this marker allowed us to (potentially) reduce some heterogeneity in response to this agent. To determine the relations between change in major endpoints and n-3 FA incorporation into tissues, we repeated the analyses using the OMX fi nal / OMX initial (i.e., the percent changes in the OMX) instead of P-OM3 treatment assignment ( Fig. 2 ). TG reductions were signifi cantly related to the increase in OMX (similar results for EPA or DHA alone were also seen), and the model fi t was improved using this metric. This demonstrates that the TG response to therapy was better explained by the change in tissue n-3 FA levels than it was by group assignment . Changes in triglycerides (TG) (including 95% CI bands) as a function of the change in omega-3 index (OMX) levels in the two groups that received P-OM3. For each group, the extent of TG lowering was in proportion to the relative increase in OMX (P = 02). The greater TG lowering with combination therapy is refl ected in the step function between treatment groups (P = 0.001). The line at y =1 represents identity, or no change from baseline. The results are shown as the least-squares fi t of the semi-log line, note the logscale of the y -axis. Using the ratios of DHA and of EPA (as fi nal/ baseline) gave similar results. N = 30; because there was no change in OMX or TG levels for subjects on placebo P-OM3, they were not included in the analysis.
although the study was well-powered to detect main effects on most lipid endpoints, there was little power to detect interactions. In other words, we were unlikely to detect effects of combination therapy beyond those that were simply additive. We also note that although we did not detect an effect of P-OM3 on nonHDL-C, our study was not powered to detect this endpoint and this should be considered in light of fi ndings from larger studies ( 13 ) . Despite randomization, baseline values for some endpoints (nonHDL-C and LDL-C in the P-OM3 group and RHI in the placebo group) were not uniform, due again to the small sample size. These imbalances may have confounded the results despite adjustment for baseline values.
In conclusion, combination therapy with ERN and POM-3 produced additive effects on serum TG and on HDL and LDL size and buoyancy. These changes are consistent with a decrease in risk for coronary events; however, further prospective trials are necessary to confi rm this.
